Foster City and Santa Monica, Calif. – February 17, 2023 – Christi Shaw has decided to leave Kite, a Gilead Company, effective end of March. Daniel O'Day, Chairman and CEO of Gilead, will work closely with Christi and the Kite leadership team over the next few weeks to ensure a smooth transition while a search is conducted for a new leader for Kite. Christi joined Kite as CEO in 2019.
"I would like to thank Christi for her leadership of Kite during what has been a strong growth phase for the company and a pivotal time for CAR T-cell therapy,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Under Christi’s leadership, Kite has become a global leader in cell therapy. Now, with an outstanding team in place, multiple approved indications and a growing pipeline, Kite is set to build on this positive momentum so it can help an increasing number of patients in the future.”
During Christi’s time leading Kite, the company has gone from treating a few hundred patients with CAR T-cell therapy to now nearly 13,000 globally with two products and five regulatory indications, including approvals in over 20 countries around the world.
“My journey with Kite has truly been the highlight of my career due to the very personal nature of cell therapy and the curative potential that it can provide patients with certain blood cancers. There is no good time to end a labor of love, but I feel I have accomplished what I came to do. Kite is flourishing and ready to enter its next chapter,” said Christi Shaw, Chief Executive Officer of Kite.
Kite, the Kite logo and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Kite, please visit the company’s website at www.kitepharma.com. Follow Kite on social media on Twitter (@KitePharma) and LinkedIn.